Oncotarget

Research Papers: Immunology:

Distinctly altered gut microbiota in the progression of liver disease

Guoxiang Xie, Xiaoning Wang, Ping Liu, Runmin Wei, Wenlian Chen, Cynthia Rajani, Brenda Y. Hernandez, Rosanna Alegado, Bing Dong, Defa Li and Wei Jia _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2016; 7:19355-19366. https://doi.org/10.18632/oncotarget.8466

Metrics: PDF 5588 views  |   HTML 7816 views  |   ?  


Abstract

Guoxiang Xie1,2, Xiaoning Wang3,4, Ping Liu3,4, Runmin Wei2, Wenlian Chen2, Cynthia Rajani2, Brenda Y. Hernandez2, Rosanna Alegado5, Bing Dong6, Defa Li6, and Wei Jia1,2,3

1 Shanghai Key Laboratory of Diabetes Mellitus and Center for Translational Medicine, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai, China

2 University of Hawaii Cancer Center, Honolulu, Hawaii, USA

3 E-institute of Shanghai Municipal Education Committee, Shanghai University of Traditional Chinese Medicine, Shanghai, China

4 Key Laboratory of Liver and Kidney Diseases (Ministry of Education), Institute of Liver Diseases, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China

5 Department of Oceanography, University of Hawaii at Manoa, Honolulu, Hawaii, USA

6 National Key Laboratory of Animal Nutrition, China Agricultural University, Beijing, China

Correspondence to:

Wei Jia, email:

Keywords: gut microbiota, lipopolysaccharides, liver disease, pathogenesis, Immunology and Microbiology Section, Immune response, Immunity

Received: January 08, 2016 Accepted: March 23, 2016 Published: March 29, 2016

Abstract

Recent studies underscore important roles of intestinal microbiota and the bacterial lipopolysaccharides (LPS) production in the pathogenesis of liver disease. However, how gut microbiota alters in response to the development of steatosis and subsequent progression to nonalcoholic steatohepatitis (NASH) and hepatocellular carcinoma (HCC) remains unclear. We aimed to study the gut microbial changes over liver disease progression using a streptozotocin-high fat diet (STZ-HFD) induced NASH-HCC C57BL/6J mouse model that is highly relevant to human liver disease. The fecal microbiota at various liver pathological stages was analyzed by 16S rDNA gene pyrosequencing. Both UniFrac analysis and partial least squares-discriminant analysis showed significant structural alterations in gut microbiota during the development of liver disease. Co-abundance network analysis highlighted relationships between genera. Spearman correlation analysis revealed that the bacterial species, Atopobium spp., Bacteroides spp., Bacteroides vulgatus, Bacteroides acidifaciens, Bacteroides uniformis, Clostridium cocleatum, Clostridium xylanolyticum and Desulfovibrio spp., markedly increased in model mice, were positively correlated with LPS levels and pathophysiological features. Taken together, the results showed that the gut microbiota was altered significantly in the progression of liver disease. The connection between the gut microbial ecology and the liver pathology may represent potential targets for the prevention and treatment of chronic liver disease and HCC.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 8466